Kenya's High Court Rules Anti-Counterfeiting Law Is Unconstitutional Because It Threatens Access To Generic Drugs

from the ACTA,-TPP-take-note dept

Back in 2009, Techdirt wrote about an interesting challenge to a then-new law against counterfeits in Kenya, on the grounds that it might be used to stop perfectly legal generic variants of drugs being imported into the country. That matters, because around 90% of drugs used in Kenya are generics, which means that blocking them would have serious implications for healthcare in that country.

Michael Geist points out that two and half years later, the court has finally delivered its verdict, and it's a great result:

Kenya's High court ruled on Friday that lawmakers must review legislation that could threaten the import of generic drugs, allowing Kenyans to continue accessing affordable medicine.
The judge specifically noted the problem mentioned above:
"The act is vague and could undermine access to affordable generic medicines since the act had failed to clearly distinguish between counterfeit and generic medicines," Judge Mumbi Ngugi said in her ruling.
As a result, Kenyan lawmakers will have to amend the bill to distinguish clearly between counterfeit and generic drugs.

That's not only a huge win for the millions of Kenyans who depend upon generics for their treatment, but it also highlights a key problem for ACTA and TPP, which both seek to grant broad powers to border officials to seize medicines without distinguishing sufficiently between counterfeits and generics.

Here's what the international humanitarian aid organization Médecins Sans Frontières (MSF) has to say about ACTA and generics (pdf):

While it is claimed that ACTA will protect against falsified medicines by allowing countries and companies to take strong measures in trademark disputes, this may in fact impede access to genuine generic medicines.
Meanwhile, MSF comments on TPP as follows (pdf):
the U.S. is requesting that TPP countries grant customs officials the ex officio right to detain shipments of medicines at the border, even in transit, if the goods are suspected of being counterfeits or if they are considered “confusingly similar” to trademarked goods.
Other countries need to follow Kenya's lead and confirm that access to vital generic medicines is a right that cannot be over-ridden by purely commercial considerations. Among other things, that means throwing out ACTA, and re-drafting TPP's dangerously vague sections dealing with counterfeit drugs.

Follow me @glynmoody on Twitter or identi.ca, and on Google+

Filed Under: acta, counterfeit, generic drugs, health care, kenya, tpp


Reader Comments

Subscribe: RSS

View by: Time | Thread


  1. identicon
    Anonymous Coward, 24 Apr 2012 @ 9:19pm

    Drug Explanation

    There are three kinds of drugs:

    1. Genuine drugs. Drugs made by the original manufacturer and using the trademarked name. The dosage stated on the packet is correct. Those drugs are generally expensive while the patent runs.

    2. Generic drugs. Drugs made by reputable manufacturers other than the original manufacturer and using the generic name. A different trademarked name might be used as well. The pharmacologically active compounds in both the genuine and the generic drugs are the same and the dosage is correctly stated. These drugs are generally out of patent and are cheap, but are just as effective as the genuine drugs.

    3. Fake drugs. Drugs made by criminals to look like genuine or generic drugs, but containing much less or zero of the pharmacologically active compounds. These drugs kill patients because patients cannot control their dosage correctly. The dosage stated on the packet is a lie. They are got into the supply chain by corrupt practices.

    Original manufacturers hate generics and fakes. But they know that it is actually only the fakes which are dangerous to patients. They dishonestly attempt to get generics and fakes treated the same.

Add Your Comment

Have a Techdirt Account? Sign in now. Want one? Register here



Subscribe to the Techdirt Daily newsletter




Comment Options:

  • Use markdown. Use plain text.
  • Remember name/email/url (set a cookie)

Follow Techdirt
Insider Shop - Show Your Support!

Advertisement
Report this ad  |  Hide Techdirt ads
Essential Reading
Techdirt Deals
Report this ad  |  Hide Techdirt ads
Techdirt Insider Chat
Advertisement
Report this ad  |  Hide Techdirt ads
Recent Stories
Advertisement
Report this ad  |  Hide Techdirt ads

Close

Email This

This feature is only available to registered users. Register or sign in to use it.